Medical technology company iRhythm Technologies (NASDAQ: IRTC) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.9% year on year to $221.6 million. On the other hand, the company’s full-year revenue guidance of $892.5 million at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.82 per share was significantly above analysts’ consensus estimates.
Is now the time to buy IRTC? Find out in our full research report (it’s free for active Edge members).
iRhythm (IRTC) Q3 2026 highlights:
- Revenue $221.6 million vs S&P analysts’ estimates of $222.3 million (14.9% year-on-year growth, in line)
- Adjusted EPS $0.82 vs S&P analysts’ estimates of $0.05 (significant beat)
- Adjusted EBITDA $51.18 million vs analyst estimates of $27.82 million (23.1% margin, 84% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $892.5 million at the midpoint from $885 million
- Operating margin -14.7%, down from -4.4% in the same quarter last year
- Market capitalization $4.29 billion
StockStory’s take
iRhythm’s third quarter brought steady revenue growth and stronger-than-expected profitability, but the market responded negatively due to concerns surrounding business momentum and outlook. Management attributed performance to continued demand for its Zio monitor, expansion into primary care and innovative channels, and operational leverage. CEO Quentin Blackford cited “durable demand and sustained momentum across primary care, innovative channels, and international markets” as key drivers. However, Zio AT revenue was flat, held back by customer delays related to the pending VitalConnect integration, and management openly acknowledged frustration with this segment’s recent stagnation.
Looking forward, iRhythm’s updated guidance reflects both the integration of the VitalConnect acquisition and persistent headwinds in its mobile cardiac telemetry segment. Management expects the addition of VitalConnect’s platform to broaden its product portfolio and customer base, but flagged that Zio AT softness may persist until the platforms are fully combined and operational. CFO Dan Wilson noted, “We will continue to balance profitability performance with targeted investments that support future growth,” while Blackford outlined plans to accelerate VitalConnect integration and address evolving customer requirements in the MCT market.
Key insights from management’s remarks
Management emphasized the quarter’s performance was shaped by strong Zio monitor growth, early VitalConnect integration activities, and ongoing Zio AT headwinds, all of which are influencing strategic priorities moving forward.
-
Zio monitor leads growth: The company’s Zio monitor continued to be the primary growth driver, benefiting from increased adoption in primary care and innovative channels, as well as international expansion. Management highlighted strong volume growth and new account wins in these segments.
-
Zio AT faces delays: Revenue from Zio AT was flat due to delayed purchasing decisions by customers awaiting the combined VitalConnect and iRhythm platform. Blackford explained that customers “do not want to go through two integrations,” driving postponements until VitalConnect is fully integrated.
-
VitalConnect acquisition accelerates: The early close of the VitalConnect deal positioned iRhythm to quickly scale its platform with additional FDA-cleared monitoring capabilities, including live look-in and multi-parameter features that address previously unmet market needs. This acquisition is expected to immediately expand the company’s MCT (mobile cardiac telemetry) offering.
-
Operational leverage and margin gains: Gross margin improved, aided in part by one-time tariff refunds and manufacturing efficiencies. Adjusted EBITDA margin reached a record level, reflecting cost discipline, automation, and scale, even as targeted investments continued in growth initiatives.
-
AI and platform innovation: Management noted ongoing investments in AI-powered diagnostic algorithms and EHR integration, with the third-generation algorithm expected to drive more than $100 million in savings over five years. These efforts aim to further improve diagnostic accuracy and workflow efficiency across the platform.
Drivers of future performance
Management’s outlook centers on integrating VitalConnect, navigating ongoing Zio AT headwinds, and scaling adoption in primary care and innovative channels.
-
VitalConnect integration pivotal: The pace and effectiveness of integrating VitalConnect’s monitoring capabilities will be a major factor. Management expects the combined portfolio to better address customer requirements for multi-parameter monitoring, but acknowledged that integration will take time and may extend current sales delays for Zio AT.
-
AT segment uncertainty: Zio AT demand is expected to remain flat in the near term as customers delay onboarding until VitalConnect is available in a unified workflow. Management believes performance could re-accelerate once the integration is complete, but cautioned that “what we are experiencing in AT [will] hang around for a quarter or two.”
-
Growth in primary care and innovative channels: Continued expansion into primary care and innovative channels is anticipated to drive mid-teens growth in the Zio monitor business. Management is investing in provider education, patient activation, and workflow integration to capture a significant portion of the identified 27-million-patient opportunity for ambulatory cardiac monitoring.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will watch (1) the speed and effectiveness of VitalConnect’s integration into a unified workflow, (2) whether Zio AT demand stabilizes and returns to growth post-integration, and (3) continued expansion in primary care and innovative channels driving Zio monitor adoption. Progress on EHR integration and commercialization of new AI algorithms will also be key markers of execution.
iRhythm currently trades at $114.06, down from $130.19 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
Our favorite stocks right now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
